TMCnet

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Le Lézard

Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIKtm (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA ...